Compare SNDL & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNDL | GLSI |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 381.0M | 327.2M |
| IPO Year | 2019 | 2020 |
| Metric | SNDL | GLSI |
|---|---|---|
| Price | $1.43 | $27.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $5.00 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 2.8M | 116.6K |
| Earning Date | 04-29-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.19 | N/A |
| Revenue Next Year | $3.08 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.15 | $7.78 |
| 52 Week High | $2.89 | $34.10 |
| Indicator | SNDL | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 48.57 | 61.75 |
| Support Level | $1.31 | $21.21 |
| Resistance Level | $1.63 | $30.08 |
| Average True Range (ATR) | 0.06 | 1.76 |
| MACD | -0.00 | 0.49 |
| Stochastic Oscillator | 54.76 | 81.15 |
SNDL Inc is a private-sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, and Spiritleaf. The principal activities of the company are the retailing of wines, beers, and spirits. It comprised four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments. Liquor retail includes the sale of wines, beers, and spirits through owned liquor stores. The company generates maximum revenue from liquor retail.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.